Clinical specificity profile for novel rapid acting antidepressant drugs.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
9
8
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Mood disorders are recurrent/chronic diseases with variable clinical remission rates. Available antidepressants are not effective in all patients and often show a relevant response latency, with a range of adverse events, including weight gain and sexual dysfunction. Novel rapid agents were developed with the aim of overcoming at least in part these issues. Novel drugs target glutamate, gamma-aminobutyric acid, orexin, and other receptors, providing a broader range of pharmacodynamic mechanisms, that is, expected to increase the possibility of personalizing treatments on the individual clinical profile. These new drugs were developed with the aim of combining a rapid action, a tolerable profile, and higher effectiveness on specific symptoms, which were relatively poorly targeted by standard antidepressants, such as anhedonia and response to reward, suicidal ideation/behaviours, insomnia, cognitive deficits, and irritability. This review discusses the clinical specificity profile of new antidepressants, namely 4-chlorokynurenine (AV-101), dextromethorphan-bupropion, pregn-4-en-20-yn-3-one (PH-10), pimavanserin, PRAX-114, psilocybin, esmethadone (REL-1017/dextromethadone), seltorexant (JNJ-42847922/MIN-202), and zuranolone (SAGE-217). The main aim is to provide an overview of the efficacy/tolerability of these compounds in patients with mood disorders having different symptom/comorbidity patterns, to help clinicians in the optimization of the risk/benefit ratio when prescribing these drugs.
Identifiants
pubmed: 37381161
doi: 10.1097/YIC.0000000000000488
pii: 00004850-990000000-00072
pmc: PMC10373854
doi:
Substances chimiques
Antidepressive Agents
0
Bupropion
01ZG3TPX31
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-328Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Abramian AM, Comenencia-Ortiz E, Modgil A, Vien TN, Nakamura Y, Moore YE, et al. (2014). Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABA A receptors. Proc Natl Acad Sci USA 111:7132–7137.
Acadia. (2020). ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder. Acadia Pharmaceuticals. https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-top-line-results-from-the-phase-3-clarity-study-evaluating-pimavanserin-for-the-adjunctive-treatment-of-major-depressive-disorder/ . [Accessed 12 September 2022]
Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 34:155–166.
Althaus AL, Ackley MA, Belfort GM, Gee SM, Dai J, Nguyen DP, et al. (2020). Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator. Neuropharmacology 181:108333.
Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams L-A, Hui K, et al. (2019). Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology (Berl) 236:731–740.
Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, et al. (2020). Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine 27:100538.
Ark PD van der, Golor G, Nueten L van, Nandy P, Boer P de (2018). Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. J Psychopharmacol 32:1330–1340.
Axsome Therapeutics2020a). Axsome therapeutics announces positive efficacy and safety results from phase 3 COMET long-term trial and COMET-AU trial of AXS-05 in major depressive disorder. GlobeNewswire News Room https://www.globenewswire.com/en/news-release/2020/12/01/2137234/33090/en/Axsome-Therapeutics-Announces-Positive-Efficacy-and-Safety-Results-from-Phase-3-COMET-Long-Term-Trial-and-COMET-AU-Trial-of-AXS-05-in-Major-Depressive-Disorder.html . [Accessed 14 September 2022]
Axsome Therapeutics2020b). Axsome Therapeutics announces positive results from the COMET-SI trial of AXS-05 in patients with major depressive disorder who have suicidal ideation. https://www.globenewswire.com/news-release/2020/12/8/2141143/0/en/Axsome-Therapeutics-Announces-Positive-Results-from-the-COMET-SI-Trial-of-AXS-05-in-Patients-with-Major-Depressive-Disorder-Who-Have-Suicidal-Ideation.html . [Accessed 14 September 2022]
Axsome Therapeutics2020c). Axsome therapeutics announces topline results of the STRIDE-1 phase 3 trial in treatment resistant depression and expert call to discuss clinical implications. GlobeNewswire News Room https://www.globenewswire.com/en/news-release/2020/03/30/2008163/33090/en/Axsome-Therapeutics-Announces-Topline-Results-of-the-STRIDE-1-Phase-3-Trial-in-Treatment-Resistant-Depression-and-Expert-Call-to-Discuss-Clinical-Implications.html . [Accessed 14 September 2022]
Axsome Therapeutics. (2021). Axsome therapeutics announces AXS-05 achieves primary and key secondary endpoints in the MERIT phase 2 trial in treatment resistant depression. GlobeNewswire News Room https://www.globenewswire.com/news-release/2021/08/09/2276951/33090/en/Axsome-Therapeutics-Announces-AXS-05-Achieves-Primary-and-Key-Secondary-Endpoints-in-the-MERIT-Phase-2-Trial-in-Treatment-Resistant-Depression.html . [Accessed 14 September 2022]
Axsome Therapeutics. (2022). Axsome therapeutics announces late-breaking presentations of positive results of the EVOLVE trial of AXS-05 in major depressive disorder after prior treatment failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting. GlobeNewswire News Room https://www.globenewswire.com/en/news-release/2022/06/01/2454061/33090/en/Axsome-Therapeutics-Announces-Late-Breaking-Presentations-of-Positive-Results-of-the-EVOLVE-Trial-of-AXS-05-in-Major-Depressive-Disorder-After-Prior-Treatment-Failures-at-the-Ameri.html . [Accessed 14 September 2022]
Ballard ED, Wills K, Lally N, Richards EM, Luckenbaugh DA, Walls T, et al. (2017). Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. J Affect Disord 218:195–200.
Bauer MS (2022). Bipolar disorder. Ann Intern Med 175:ITC97–ITC112.
Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Träskman-Bendz L, Guillemin GJ, et al. (2015). A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality. Brain Behav Immun 43:110–117.
Beck CT (2006). Postpartum depression. Am J Nurs 106:40–50.
Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, et al. (2022). Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther 111:886–895.
Bernstein G, Davis K, Mills C, Wang L, McDonnell M, Oldenhof J, et al. (2019). Characterization of the safety and pharmacokinetic profile of d-methadone, a novel N-Methyl-d-aspartate receptor antagonist in healthy, opioid-naive subjects. J Clin Psychopharmacol 39:226–237.
Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, et al. (2015). Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J Pharmacol Exp Ther 354:471–482.
Botella GM, Salituro FG, Harrison BL, Beresis RT, Bai Z, Blanco M-J, et al. (2017). Neuroactive steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1 H -pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (γ-Aminobutyric Acid) A receptor. J Med Chem 60:7810–7819.
Boulougouris V, Glennon JC, Robbins TW (2008). Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology 33:2007–2019.
Brooks S, Jacobs GE, Boer P. de, Kent JM, Nueten LV, Amerongen G van, et al. (2019). The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J Psychopharmacol 33:202–209.
Brown SJ, Huang X-F, Newell KA (2021). The kynurenine pathway in major depression: what we know and where to next. Neurosci Biobehav Rev 127:917–927.
Bullock A, Gunduz-Bruce H, Zammit GK, Qin M, Li H, Sankoh AJ, et al. (2022). A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults. Hum Psychopharmacol - Clin Exp 37:e2806.
Buoli M, Rovera C, Pozzoli SM, Fiorentini A, Cremaschi L, Caldiroli A, et al. (2019). Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration. CNS Spectr 24:258–264.
Buyukdura JS, McClintock SM, Croarkin PE (2011). Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. Prog Neuropsychopharmacol Biol Psychiatry 35:395–409.
Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, et al. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 8:20.
Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ (2015). LSD enhances suggestibility in healthy volunteers. Psychopharmacology (Berl) 232:785–794.
Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3:619–627.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. (2021). Trial of psilocybin versus escitalopram for depression. N Engl J Med 384:1402–1411.
Carta MG, Bhat KM, Preti A (2012). GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behav Brain Funct 8:61.
Caruso D, Masci I, Cipollone G, Palagini L (2019). Insomnia and depressive symptoms during the menopausal transition: theoretical and therapeutic implications of a self-reinforcing feedback loop. Maturitas 123:78–81.
Castle D, Beilharz F, Phillips KA, Brakoulias V, Drummond LM, Hollander E, et al. (2021). Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. Int Clin Psychopharmacol 36:61–75.
clinicaltrials.gov. (2017). A 6-month, multicenter, double-blind, randomized, flexible-dose, parallel-group study to compare the efficacy, safety, and tolerability of JNJ-42847922 versus quetiapine extended-release as adjunctive therapy to antidepressants in adult subjects with major depressive disorder who have responded inadequately to antidepressant therapy. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov. (2018). Psilocybin and depression – assessing the long-term effects of a single administration of psilocybin on the psychiatric symptoms and brain activity of patients with severe depression. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2019a). A randomized, double-blind, support-of-concept phase 2 study of single-dose psilocybin for major depressive disorder (MDD). clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2019b). Phase II, randomized, double blind, placebo controlled, parallel group, single center study of psilocybin efficacy in major depression. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2020a). A multicenter, double-blind, randomized, parallel-group, placebo-controlled, study to evaluate the efficacy and safety of seltorexant 20 mg as adjunctive therapy to antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms who have responded inadequately to antidepressant therapy. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2020b). A multicenter, double-blind, randomized, parallel-group, placebo-controlled, study to evaluate the efficacy and safety of seltorexant 20 mg as adjunctive therapy to antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms who have responded inadequately to antidepressant therapy and an open-labeled long-term safety extension treatment with seltorexant. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2020c). A multicentric, randomized, double-blind, placebo- and positive-controlled 4-way crossover study to evaluate the effects of single and repeated administration of oral seltorexant as an add-on medication to an antidepressant on on-road driving performance in participants with major depressive disorder. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2020d). A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of SAGE-217 in the treatment of adults with severe postpartum depression. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2020e). Double-blind, randomized, parallel-group study with quetiapine extended release as comparator to evaluate the efficacy and safety of seltorexant 20 mg as adjunctive therapy to antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms who have responded inadequately to antidepressant therapy. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2021a). A phase 2 double-blind, placebo-controlled, dose-ranging clinical trial to evaluate the efficacy and safety of PRAX-114 in adjunctive and monotherapy treatment of participants with major depressive disorder and inadequate response to antidepressant treatment. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2021b). A phase II randomized, double-blind, active placebo-controlled parallel group trial to examine the efficacy and safety of psilocybin in treatment-resistant major depression. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2021c). A randomized, active-controlled, evaluation of AXS-05 for the treatment of treatment resistant depression in treatment-adherent patients. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2021d). A short-term exploratory study to evaluate safety, tolerability and pharmacokinetics of seltorexant as adjunctive therapy to antidepressants in adolescents with major depressive disorder who have an inadequate response to SSRI monotherapy and psychotherapy. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2021e). Psilocybin treatment of major depressive disorder with co-occurring alcohol use disorder. clinicaltrials.gov. [Accessed 16 September 2022]
clinicaltrials.gov2021f). The effect of psilocybin on MDD symptom severity and synaptic density - a single dose randomized, double blind, placebo- controlled phase 2 positron emission tomography study. clinicaltrials.gov. [Accessed 16 September 2022]
COMPASS Pathways, (2021). COMPASS pathways announces positive topline results from groundbreaking phase 2b trial of investigational COMP360 psilocybin therapy for treatment-resistant depression.. https://compasspathways.com/https://compasspathways.com/positive-topline-results/ .[Accessed 10 September 2022]
Cusi AM, MacQueen GM, Spreng RN, McKinnon MC (2011). Altered empathic responding in major depressive disorder: relation to symptom severity, illness burden, and psychosocial outcome. Psychiatry Res 188:231–236.
DeKarske D, Alva G, Aldred JL, Coate B, Cantillon M, Jacobi L, et al. (2020). An open-label, 8-week study of safety and efficacy of pimavanserin treatment in adults with Parkinson’s disease and depression. J Parkinsons Dis 10:1751–1761.
Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, et al. (2021). Effect of zuranolone vs placebo in postpartum depression. JAMA Psychiatry 78:951–959.
Doblin RE, Christiansen M, Jerome L, Burge B (2019). The past and future of psychedelic science: an introduction to this issue. J Psychoactive Drugs 51:93–97.
Dörks M, Hoffmann F, Jobski K (2022). Antidepressant drug use and regional prescribing patterns in Germany: results from a large population-based study. Int Clin Psychopharmacol 37:185–192.
Doss MK, Považan M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, et al. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry 11:574.
Egede LE, Bishu KG, Walker RJ, Dismuke CE (2016). Impact of diagnosed depression on healthcare costs in adults with and without diabetes: United States, 2004-2011. J Affect Disord 195:119–126.
European Medicines Agency (EMA) (2003). Evaluation of Medicines for human use, positio paper on non-clinical safety studies to support clinical trials with a single microdose. https://iaa-ams.co.jp/wpcontent/uploads/2020/10/MD1.pdf . [Accessed 29 September 2022].
Fanelli G, Serretti A (2022). Depression, antidepressants, and insulin resistance: which link? Eur Neuropsychopharmacol 60:4–6.
Fanelli G, Domschke K, Minelli A, Gennarelli M, Martini P, Bortolomasi M, et al. (2022). A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. Eur Neuropsychopharmacol 55:86–95.
Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, et al. (2019). A phase 2, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY). J Clin Psychiatry 80:19m12928.
Fava M, Stahl S, Pani L, Martin SD, Pappagallo M, Guidetti C, et al. (2022). REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial. Am J Psychiatry 179:122–131.
Flanigan ME, Aleyasin H, Li L, Burnett CJ, Chan KL, LeClair KB, et al. (2020). Orexin signaling in GABAergic lateral habenula neurons modulates aggressive behavior in male mice. Nat Neurosci 23:638–650.
Fogaça MV, Fukumoto K, Franklin T, Liu R-J, Duman CH, Vitolo OV, et al. (2019). N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology 44:2230–2238.
Freeman MP, Fava M, Dirks B, Jha MK, Papakostas GI, Shelton RC, et al. (2020). Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: a secondary analysis. Depress Anxiety 37:485–495.
Frieder A, Fersh M, Hainline R, Deligiannidis KM (2019). Pharmacotherapy of postpartum depression: current approaches and novel drug development. CNS Drugs 33:265–282.
Gagliardi L, Petrozzi A, Rusconi F (2012). Symptoms of maternal depression immediately after delivery predict unsuccessful breast feeding: Figure 1. Arch Dis Child 97:355–357.
Gaynes BN, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J, et al. (2020). Defining treatment-resistant depression. Depress Anxiety 37:134–145.
Goetz T., Arslan A., Wisden W., Wulff P. (2007). GABAA receptors: structure and function in the basal ganglia. In: Progress in brain research. Elsevier. pp. 21–41.
Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR (2020). The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res 284:112749.
Gorman AL, Elliott KJ, Inturrisi CE (1997). The d- and l- isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 223:5–8.
Griffiths RR, Richards WA, McCann U, Jesse R (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268–83; discussion 284.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30:1181–1197.
Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, et al. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol 32:49–69.
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71–78.
Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, et al. (2019). Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 381:903–911.
Gunduz-Bruce H, Lasser R, Nandy I, Sankoh A, Jonas J, Doherty J, Kanes S (2020). Open-label, phase 2 trial of the oral neuroactive steroid GABAA receptor positive allosteric modulator zuranolone in bipolar disorder I and II. HMP Global Learning Network. https://www.hmpgloballearningnetwork.com/site/pcn/posters/open-label-phase-2-trial-oral-neuroactive-steroid-gabaa-receptor-positive-allosteric . [Accessed 1 September 2022]
Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.
Harvey JA (2003). Role of the serotonin 5-HT 2A receptor in learning. Learn Mem 10:355–362.
Hecking J, Davoudian PA, Wilkinson ST (2021). Emerging therapeutics based on the amino acid neurotransmitter system: an update on the pharmaceutical pipeline for mood disorders. Chronic Stress 5:247054702110204.
Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, et al. (2004). Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression. J Clin Psychiatry 65:959–965.
Hughes Z, Scott L, Kahlig K, Wittmann M (2021). PRAX-114 is a novel extrasynaptic GABA-A receptor preferring positive allosteric modulator with a wide separation between a translational biomarker signature associated with antidepressant-like activity, and sedative effects. Biol Psychiatry 89:S204.
Iosifescu DV, Jones A, O’Gorman C, Streicher C, Feliz S, Fava M, et al. (2022). Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder. J Clin Psychiatry 83:21m14345.
James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858.
Jha MK, Fava M, Freeman MP, Thase ME, Papakostas GI, Shelton RC, et al. (2020). Effect of adjunctive pimavanserin on sleep/wakefulness in patients with major depressive disorder. J Clin Psychiatry 82:20m13425.
Johnson PL, Molosh A, Fitz SD, Truitt WA, Shekhar A (2012). Orexin, stress, and anxiety/panic states. Prog Brain Res 198:133–161.
Krusemark EA, Novak LR, Gitelman DR, Li W (2013). When the sense of smell meets emotion: anxiety-state-dependent olfactory processing and neural circuitry adaptation. J Neurosci 33:15324–15332.
Kuriyama A, Tabata H (2017). Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis. Sleep Med Rev 35:1–7.
Lee S-Y, Wang T-Y, Chen S-L, Chang Y-H, Chen P-S, Huang S-Y, et al. (2020). Combination of dextromethorphan and memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial. Int J Bipolar Disord 8:11.
Liebowitz MR, Hanover R, Draine A, Lemming R, Careri J, Monti L (2016). Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder. Depress Anxiety 33:1081–1089.
Luscher B, Shen Q, Sahir N (2011). The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 16:383–406.
Lyons T, Carhart-Harris RL (2018). More realistic forecasting of future life events after psilocybin for treatment-resistant depression. Front Psychol 9:1721.
Machado-Vieira R, Salvadore G, DiazGranados N, Zarate CA (2009). Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123:143–150.
Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G, et al. (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349–352.
Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. (2021). Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. Expert Opin Emerg Drugs 26:63–74.
Mardi J. (2022). BioPharma Media, 2022. BioPharma Media. https://biopharma.media/auvelity-new-antidepressant-for-most-severe-depression-4068/ . [Accessed 8 September 2022]
Marschall J, Fejer G, Lempe P, Prochazkova L, Kuchar M, Hajkova K, et al. (2022). Psilocybin microdosing does not affect emotion-related symptoms and processing: a preregistered field and lab-based study. J Psychopharmacol 36:97–113.
McClintock SM, Husain MM, Wisniewski SR, Nierenberg AA, Stewart JW, Trivedi MH, et al. (2011). Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 31:180–186.
McIntyre RS, Calabrese JR (2019). Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin 35:1993–2005.
McIntyre RS, Lee Y, Mansur RB (2016). A pragmatic approach to the diagnosis and treatment of mixed features in adults with mood disorders. CNS Spectr 21:25–33.
Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389.
Monti L, Nicolini H, Liebowitz MR, Hanover R (2019). A placebo controlled trial of PH10: test of a new rapidly acting intranasally administered antidepressant. Br J Pharm Res 04:2157–2168.
Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67:1735–1740.
Murphy N, Ramakrishnan N, Vo-Le B, Vo-Le B, Smith MA, Iqbal T, et al. (2021). A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-d-aspartate receptor blockade in healthy veterans. Neuropsychopharmacology 46:820–827.
Nemeroff CB (2022). Back to the future: esmethadone, the (maybe) nonopiate opiate, and depression. Am J Psychiatry 179:83–84.
Nguyen L, Matsumoto RR (2015). Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. Behav Brain Res 295:26–34.
Nollet M, Leman S (2013). Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. CNS Drugs 27:411–422.
Oh C-M, Kim HY, Na HK, Cho KH, Chu MK (2019). The effect of anxiety and depression on sleep quality of individuals with high risk for insomnia: a population-based study. Front Neurol 10:849.
Papakostas GI, Fava M, Freeman MP, Shelton RC, Thase ME, Jha MK, et al. (2020). Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. Int Clin Psychopharmacol 35:313–321.
Park LT, Kadriu B, Gould TD, Zanos P, Greenstein D, Evans JW, et al. (2020). A randomized trial of the N-Methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression. Int J Neuropsychopharmacol 23:417–425.
Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, et al. (1995). Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239–1258.
Passie T, Seifert J, Schneider U, Emrich HM (2002). The pharmacology of psilocybin. Addict Biol 7:357–364.
Pause BM, Miranda A, Göder R, Aldenhoff JB, Ferstl R (2001). Reduced olfactory performance in patients with major depression. J Psychiatr Res 35:271–277.
Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX (2017). Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol 20:747–757.
Pourhamzeh M, Moravej FG, Arabi M, Shahriari E, Mehrabi S, Ward R, et al. (2022). The roles of serotonin in neuropsychiatric disorders. Cell Mol Neurobiol 42:1671–1692.
Praxis. (2021). Praxis precision medicines reports PRAX-114 perimenopausal depression (PMD) phase 2a proof-of-concept trial results and announces plans to advance to phase 2b study in women with menopausal and mood symptoms. Praxis Precision Medicines, Inc. https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-reports-PRAX-114-perimenopausal/ . [Accessed 17 September 2022]
Praxis. (2022). Praxis precision medicines reports negative results from PRAX-114 phase 2/3 monotherapy aria study in patients with major depressive disorder. Praxis Precision Medicines, Inc. https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-reports-negative-results-PRAX-114/ . [Accessed 17 September 2022]
Radoš SN (2018). Anxiety during pregnancy and postpartum: course, predictors and comorbidity with postpartum depression. Acta Clinica Croatica 57:39–51.
Recourt K, Boer P. de, Zuiker R, Luthringer R, Kent J, Ark P. van der, et al. (2019). The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry 9:216.
Reddy D.S. (2018). GABA-A receptors mediate tonic inhibition and neurosteroid sensitivity in the brain. In: Vitamins and hormones. Elsevier, pp. 177–191.
Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T (2018). Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry 81:1–10.
Réus GZ, Jansen K, Titus S, Carvalho AF, Gabbay V, Quevedo J (2015). Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies. J Psychiatr Res 68:316–328.
Rissardo JP, Durante I, Sharon I, Caprara ALF (2022). Pimavanserin and Parkinson’s disease psychosis: a narrative review. Brain Sci 12:1286.
Ross S (2018). Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry 30:317–330.
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30:1165–1180.
Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, et al. (2021). Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer. ACS Pharmacol Transl Sci 4:553–562.
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. (2003). The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573–583.
Sage Therapeutics. (2019). Sage therapeutics reports topline results from pivotal phase 3 MOUNTAIN study of SAGE-217 in major depressive disorder. Sage Therapeutics, Inc. https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-reports-topline-results-pivotal-phase-3 . [Accessed 23 September 2022]
Sage Therapeutics. (2022). Sage therapeutics announces second quarter 2022 financial results and highlights pipeline and business progress. Sage Therapeutics, Inc. https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-second-quarter-2022-financial . [Accessed 23 September 2022]
Sage Therapeutics, Biogen2021a). Sage therapeutics and biogen announce positive, one-year zuranolone 50 mg data in the ongoing open-label SHORELINE study in patients with MDD. https://www.businesswire.com/news/home/20211201005365/en/Sage-Therapeutics-and-Biogen-Announce-Positive-One-Year-Zuranolone-50-mg-Data-in-the-Ongoing-Open-Label-SHORELINE-Study-in-Patients-with-MDD . [Accessed 23 September 2022]
Sage Therapeutics, Biogen2021b). Sage therapeutics and biogen announce positive pivotal phase 3 results for zuranolone, an investigational two-week, once-daily therapeutic being evaluated for major depressive disorder. Biogen. https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3 . [Accessed 23 September 2022]
Sage Therapeutics, Biogen. (2022). Sage therapeutics and biogen announce the phase 3 CORAL study met its primary and key secondary endpoints – comparing zuranolone 50 mg co-initiated with standard of care antidepressant vs. standard of care co-initiated with placebo in people with MDD. Biogen. https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-phase-3-coral-study-met . [Accessed 23 September 2022]
Sakashita Y, Abe K, Katagiri N, Kambe T, Saitoh T, Utsunomiya I, et al. (2015). Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats. Biol Pharm Bull 38:134–138.
Salituro FG, Tomlinson RC, Baron BM, Palfreyman MG, McDonald IA, Schmidt W, et al. (1994). Enzyme-activated antagonists of the strychnine-insensitive glycine/NMDA receptor. J Med Chem 37:334–336.
Savitz A, Wajs E, Zhang Y, Xu H, Etropolski M, Thase ME, et al. (2021). Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study. Int J Neuropsychopharmacol 24:965–976.
Serretti A, Chiesa A (2009). Treatment-emergent sexual dysfunction related to antidepressants. J Clin Psychopharmacol 29:259–266.
Serretti A, Mandelli L (2010). Antidepressants and body weight. J Clin Psychiatry 71:1259–1272.
Shelton RC, Fava M, Freeman MP, Thase ME, Papakostas GI, Jha MK, et al. (2020). Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: analysis of the CLARITY study. J Affect Disord 277:478–485.
Siegel AN, Vincenzo JDD, Brietzke E, Gill H, Rodrigues NB, Lui LMW, et al. (2021). Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: a systematic review. J Psychiatr Res 137:426–436.
Stachowicz K, Sowa-Kućma M (2022). The treatment of depression – searching for new ideas. Front Pharmacol 13:988648.
Stahl SM (2019). Dextromethorphan/bupropion: a novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity. CNS Spectr 24:461–466.
Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, et al. (2018). Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology (Berl) 235:459–466.
Studerus E, Gamma A, Kometer M, Vollenweider FX (2012). Prediction of psilocybin response in healthy volunteers. PLoS One 7:e30800.
Sutton E (2015). Profile of suvorexant in the management of insomnia. Drug Des Devel Ther 9:6035.
Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV (2022). Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry 179:490–499.
Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR (2016). Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther 164:170–182.
Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, et al. (2006). Pharmacological and behavioral profile of N -(4-Fluorophenylmethyl)- N -(1-methylpiperidin-4-yl)- N′ -(4-(2-methylpropyloxy)phenylmethyl) carbamide (2 R ,3 R )-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine 2A receptor inverse agonist. J Pharmacol Exp Ther 317:910–918.
Veen B.T.H. de, Schellekens AFA, Verheij MMM, Homberg JR (2017). Psilocybin for treating substance use disorders? Expert Rev Neurother 17:203–212.
VistaGen Therapeutics. (2019). VistaGen reports topline phase 2 results for AV-101 as an adjunctive treatment of major depressive disorder. https://www.prnewswire.com/news-releases/vistagen-reports-topline-phase-2-results-for-av-101-as-an-adjunctive-treatment-of-major-depressive-disorder-300958317.html . [Accessed 25 September 2022]
Vliegen N, Casalin S, Luyten P (2014). The course of postpartum depression. Harv Rev Psychiatry 22:1–22.
Walsh JL, Hui-Qiu W, Ungerstedt U, Schwarcz R (1994). 4-chloro-3-hydroxyanthranilate inhibits quinolinate production in the rat hippocampus in vivo. Brain Res Bull 33:513–516.
WHO depressive disorder. (2023). Fact sheets/detail/depressive disorder (depression). https://www.who.int/news-room/fact-sheets/detail/depression . [Accessed 2 September 2022]
Wimberley T, Horsdal HT, Brikell I, Laursen TM, Astrup A, Fanelli G, et al. (2022). Temporally ordered associations between type 2 diabetes and brain disorders – a Danish register-based cohort study. BMC Psychiatry 22:573.
Zanos P, Piantadosi SC, Wu H-Q, Pribut HJ, Dell MJ, Can A, et al. (2015). The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/Glycine B -site inhibition. J Pharmacol Exp Ther 355:76–85.